{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:30:42Z","timestamp":1787563842540,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019890","name":"University of Miyazaki Hospital","doi-asserted-by":"publisher","award":["R5"],"award-info":[{"award-number":["R5"]}],"id":[{"id":"10.13039\/100019890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006452","name":"University of Miyazaki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006452","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myeloid and lymphoid neoplasms associated with\n                    <jats:italic>FGFR1<\/jats:italic>\n                    abnormalities (MLN-\n                    <jats:italic>FGFR1<\/jats:italic>\n                    abnormalities) are rare hematologic malignancies associated with chromosome 8p11.2 abnormalities. Translocations of 8p11.2 were detected in 10 of 17,039 (0.06%) unique patient cytogenetic studies performed at nine institutions in Japan. No inversions or insertions of 8p11.2 were detected. Among the 10 patients with 8p11.2 translocations, three patients were diagnosed with MLN-\n                    <jats:italic>FGFR1<\/jats:italic>\n                    abnormalities, which were confirmed by FISH analysis. Peripheral blood eosinophilia was observed in all three patients, and all progressed to AML or T-lymphoblastic lymphoma\/leukemia. The prevalence of 8p11.2 translocations in clinical practice and the proportion of MLN-\n                    <jats:italic>FGFR1<\/jats:italic>\n                    abnormalities in patients with 8p11.2 translocations in Japan were consistent with those in previous reports from Western countries.\n                  <\/jats:p>","DOI":"10.1007\/s12185-024-03740-0","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:02:11Z","timestamp":1709888531000},"page":"722-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan"],"prefix":"10.1007","volume":"119","author":[{"given":"Kensuke","family":"Usuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michikazu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-8188","authenticated-orcid":false,"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"3740_CR1","doi-asserted-by":"publisher","first-page":"1015792","DOI":"10.3389\/fonc.2022.1015792","volume":"12","author":"T Li","year":"2022","unstructured":"Li T, Zhang G, Zhang X, Lin H, Liu Q. The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy. Front Oncol. 2022;12:1015792.","journal-title":"Front Oncol"},{"key":"3740_CR2","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"2","key":"3740_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280\u2013300.","journal-title":"Med Res Rev"},{"key":"3740_CR4","unstructured":"Nonaka M, Kawano N, Hisakata N, Mizutani S, Kugimiya H, Takigawa K, et al. Eight p11 myeloproliferative syndrome (EMS) that initially manifested as angioimmunoblastic T-cell lymphoma (AITL) and subsequently transformed into MDS\/MPN complicating with t (8;13) (p11.2; q12). J Japanese Soc Lab Hematol. 2023;24(3):440\u20137."},{"key":"3740_CR5","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, et al. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010;85(4):238\u201342.","DOI":"10.1002\/ajh.21631"},{"issue":"3","key":"3740_CR6","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1002\/ajh.24276","volume":"91","author":"C Baldazzi","year":"2016","unstructured":"Baldazzi C, Luatti S, Paolini S, Papayannidis C, Marzocchi G, Ameli G, et al. FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. Am J Hematol. 2016;91(3):E14\u20136.","journal-title":"Am J Hematol"},{"issue":"3","key":"3740_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","volume":"5","author":"S Roumiantsev","year":"2004","unstructured":"Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, et al. Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5(3):287\u201398.","journal-title":"Cancer Cell"},{"issue":"12","key":"3740_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2009-05-217182","volume":"116","author":"H Agerstam","year":"2010","unstructured":"Agerstam H, Jaras M, Andersson A, Johnels P, Hansen N, Lassen C, et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood. 2010;116(12):2103\u201311.","journal-title":"Blood"},{"issue":"8","key":"3740_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","volume":"23","author":"K Umino","year":"2018","unstructured":"Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, et al. Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018;23(8):470\u20137.","journal-title":"Hematology"},{"issue":"5","key":"3740_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33(5):522\u201333.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"3740_CR11","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1182\/blood-2022-163099","volume":"140","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Gotlib J, Vannucchi AM, Rambaldi A, Reiter A, Shomali W, et al. FIGHT-203, an ongoing phase 2 study of pemigatinib in patients with Myeloid\/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): a focus on centrally reviewed clinical and cytogenetic responses in previously treated patients. Blood. 2022;140(Suppl 1):3980\u20132.","journal-title":"Blood"},{"issue":"1","key":"3740_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng0996-33","volume":"14","author":"J Borrow","year":"1996","unstructured":"Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14(1):33\u201341.","journal-title":"Nat Genet"},{"issue":"8","key":"3740_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/leu.2008.128","volume":"22","author":"C Gervais","year":"2008","unstructured":"Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, et al. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique. Leukemia. 2008;22(8):1567\u201375.","journal-title":"Leukemia"},{"issue":"5","key":"3740_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Can Res. 2010;70(5):2085\u201394.","journal-title":"Can Res"},{"issue":"5","key":"3740_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251202","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, Ai LS, Zhou LQ. Prognostic value of FGFR1 expression and amplification in patients with HNSCC: a systematic review and meta-analysis. PLoS ONE. 2021;16(5): e0251202.","journal-title":"PLoS ONE"},{"issue":"12","key":"3740_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/modpathol.2014.71","volume":"27","author":"PA Russell","year":"2014","unstructured":"Russell PA, Yu Y, Young RJ, Conron M, Wainer Z, Alam N, et al. Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. Mod Pathol. 2014;27(12):1621\u201331.","journal-title":"Mod Pathol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03740-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:02:11Z","timestamp":1716984131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03740-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3740"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03740-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}